Balchem Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Theodore Lee Harris
- Full Time Employees
- 1,379
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 52 Sunrise Park Road Montvale NY United States of America 10958
- IPO Date
- Jun 3, 1986
- CIK
- 0000009326
- Website
- balchem.com
- Similar Companies
- Business
- Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products primarily for the human and animal nutrition, food, pharmaceutical, and industrial markets. Its core product offerings include choline-based ingredients such as VitaCholine®, specialty vitamin K2 under the K2Vital® brand, MSM products branded as OptiMSM®, chelated minerals under the Albion® name, and other nutritional supplements designed for health and performance applications across food, dietary supplements, and animal feed sectors. The company also provides encapsulation technologies and microencapsulation for targeted nutrient delivery. Balchem operates through three main business segments: Human Nutrition & Health, which provides customized ingredients for food, beverage, and dietary supplements; Animal Nutrition & Health, offering precision nutrition ingredients and feed additives for livestock and companion animals; and Specialty Products, supplying specialty-packaged chemicals for healthcare, industrial, and agricultural markets. Founded in 1967 and headquartered in New Hampton, New York, Balchem serves a global customer base with operations extending across the United States, Europe, and other international markets. The company has expanded its portfolio substantially through strategic acquisitions, including the 2022 acquisition of Kappa Bioscience, a specialist in vitamin K2 production based in Norway, and Bergstrom Nutrition, a leading MSM manufacturer based in Washington State. Recent major developments include the launch of innovative products such as K2Vital® Delta Fermented, VitaCholine® Pro-Flo (a microencapsulated choline ingredient for multivitamins), Optifolin+® (a choline-enriched bioactive), and AminoShure®-XL, a next-generation rumen-protected lysine for dairy cattle nutrition. Balchem also unveiled a refreshed brand identity in 2024 emphasizing its flagship ingredients and their applications in health and wellness. Additionally, Balchem announced plans to build a new $36 million state-of-the-art facility for food ingredient and nutraceutical microencapsulation to support growth and innovation. These recent expansions and product innovations underscore Balchem’s strategic focus on science-backed specialty ingredients to meet evolving consumer demands in health, nutrition, and performance markets globally while advancing its leadership in both human and animal nutrition sectors. Balchem maintains a strong emphasis on research and development and leverages its acquisitions to enhance its specialty ingredient portfolio and geographic reach. This strategy supports its sustained revenue growth and market position in the specialty nutrition industry.
Balchem Corporation to Participate in the Wells Fargo Industrials Conference on June 10, 2026
Balchem Corporation (BCPC) Q1 2026 Earnings Call Transcript
Balchem Corporation Reports First Quarter 2026 Financial Results
Sherwin-Williams (SHW) Beats Q1 Earnings and Revenue Estimates
Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings
Balchem Corporation Releases 2025 Sustainability Report
Balchem: An Attractive Valuation Makes This Stock A Buy
Balchem Launches Metalosate® T.E.A.M.™ Plant Tissue Analysis Digital Platform to Deliver Research-Driven Nutrient Recommendations for Specialty Crops
Balchem Stock Lands New $18 Million Investor as Firm Delivers Record $1 Billion in Sales
Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
Balchem Corporation (BCPC) Q4 2025 Earnings Call Transcript
First Look: Amazon tops Walmart; WBD--Netflix saga; oil up
Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026
Statement on new EU choline chloride anti-dumping measures
Balchem Director Sells 8,000 Shares for $1.2 Million a Week Before a Dividend Hike
Balchem Corporation to Present at Baird's 55th Annual Global Industrial Conference on November 12, 2025
Balchem: Bullish On Q3 Outperformance And Favorable Outlook (Upgrade)
Balchem Corporation (BCPC) Q3 2025 Earnings Call Transcript